Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-10-06 pm EDT
43.09 USD   -2.33%
04:45pCOVID rebound after Pfizer treatment likely due to robust immune response, study finds
RE
01:57pCOVID wave looms in Europe as booster campaign makes slow start
RE
02:35aBioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer spending spree filters to Biopharma

08/10/2022 | 01:21am EDT

LIFE science debt investor Biopharma Credit has snagged a more than £30m windfall thanks to Pfizer's latest billion-dollar deal.

Pfizer, now flush with Covid-19 cash, confirmed on Monday it had bought Global Blood Therapeutics (GBT) for $5.4bn (£4.4bn).

UK-based Biopharma has $132.5m in a senior secured loan to GBT and now expects to receive an around $38m paydown this autumn, the trust's investment manager said yesterday.

Global pharmaceutical and life science sectors have been among the pandemic's biggest winners, having seen strong inflows of investment.

Pfizer expects to finance the latest transaction with "existing cash on hand", as it continues to reap billions each quarter from its Covid-19 jab and pill.

With the pandemic's larger players going on their anticipated spending sprees, onlookers have long said that M&A in the space will trickle down the pharma's small and mid-cap firms.

(c) 2022 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
GLOBAL BLOOD THERAPEUTICS, INC. 0.01% 68.49 Delayed Quote.133.99%
PFIZER, INC. -2.33% 43.09 Delayed Quote.-27.03%
All news about PFIZER, INC.
04:45pCOVID rebound after Pfizer treatment likely due to robust immune response, study finds
RE
01:57pCOVID wave looms in Europe as booster campaign makes slow start
RE
02:35aBioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment
MT
02:18aKyodo News Digest : Oct. 6, 2022 -2-
AQ
10/05Global markets live: Pfizer, Twitter, Tesco, Blackstone, Sixt...
MS
10/05Correction ( : Vaccine UPDATE1:)
AQ
10/05Pfizer Completes Acquisition of Global Blood Therapeutics 
BU
10/05Update1 : Japan approves Pfizer's BA.5-tailored COVID-19 vaccine
AQ
10/05Covid-19 : Is The IP Truce Over?
AQ
10/05Japan's Health Ministry Recommends Pfizer/BioNTech COVID-19 Jab For Children Over Six M..
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 33 370 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,61x
Yield 2022 3,76%
Capitalization 242 B 242 B -
EV / Sales 2022 2,28x
EV / Sales 2023 2,82x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 43,09 $
Average target price 55,75 $
Spread / Average Target 29,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-27.03%247 617
JOHNSON & JOHNSON-5.35%434 104
ELI LILLY AND COMPANY20.11%315 249
ROCHE HOLDING AG-13.48%273 724
ABBVIE INC.5.86%253 421
NOVO NORDISK A/S7.88%237 650